Skip to content
Sign in
Health · Global

BRIC-RGCB wins ₹7 crore to develop automated cervical cancer blood test

Researchers at BRIC-RGCB in Thiruvananthapuram secured a ₹7 crore grant to develop an automated blood-test device for detecting early signs of cervical cancer. The proposed system is not yet fully developed or validated and is intended to analyse a blood sample automatically.

AI-assisted synthesis · Based on 3 outlets' reporting · Article text read from 2 of 3 outletsHow it's made

View timeline · 7 entries
3 outletsLatest reporting 3 min read
Coverage: Too few ratedL 0 · C 2 · R 0 · 1 unrated
Updat3 graphic: BRIC-RGCB
Updat3 graphic

What happened

Key facts

  • The planned device is an automated diagnostic system intended to detect early signs of cervical cancer (per theindianpractitioner.com, The New Indian Express).
  • The planned process involves a patient providing a blood sample for automated analysis after the device is fully developed and validated (per theindianpractitioner.com, The New Indian Express).

The brief

Researchers at BRIC-Rajiv Gandhi Centre for Biotechnology in Thiruvananthapuram secured a ₹7 crore grant to develop an automated device intended to detect early signs of cervical cancer from a blood sample. The award funds development of a proposed diagnostic platform; it is not a report of a finished or clinically validated test.

The New Indian Express says the device is designed to identify piRNA-based biomarkers in blood and analyse them using nanopore technology. Its account describes a system that would automate analysis after a patient provides a blood sample, once the device has been fully developed and validated.

The work is intended to make the technology usable beyond specialised laboratory settings, project lead researcher Dr Jackson James said. The project is being carried out with IndZita Biotech Pvt Ltd in Thiruvananthapuram and Karkinos Healthcare Pvt Ltd in Mumbai.

It is supported by the MAHA MedTech Mission, which The New Indian Express says was launched by the Anusandhan National Research Foundation, Indian Council of Medical Research and the Gates Foundation. These named partners and the mission form the documented institutional framework for the research.

The Indian Practitioner reports that the Anusandhan National Research Foundation received more than 1,000 proposals and selected 33 for support. It quotes Dr. Beena Pillai, Director of RGCB, expressing pride in the research team’s success in securing the grant.

The account also describes the project as intended to support screening and early detection in places with limited conventional laboratory infrastructure. The New Indian Express says the planned blood test could reduce the need for invasive procedures and specialised technical expertise.

The Hindu’s headline characterises the technology as rapid and biopsy-free, while the other reporting describes the intended blood-sample and automated-analysis process. Those descriptions concern the proposed device, not demonstrated performance. Both written accounts place the project at an early development stage: the system still needs to be fully developed and validated.

The central next step documented by the researchers’ stated plan is therefore to develop and validate the device before the proposed automated blood-sample process can be used. The coverage does not provide clinical performance results or a timetable for that work.

Why it matters

  • The proposed blood-sample test is intended to detect early signs of cervical cancer, with automated analysis that could be used beyond specialised laboratory settings.
  • BRIC-RGCB received ₹7 crore to develop the device; the reported plan links the funding to a diagnostic approach based on piRNA biomarkers and nanopore analysis.
  • The Anusandhan National Research Foundation selected 33 proposals from more than 1,000, placing the research among a small share of proposals supported in that selection.

What to watch next

  • Whether BRIC-RGCB and its project partners develop and validate the proposed device.
  • Whether the planned piRNA biomarker and nanopore analysis is incorporated into the completed system.
  • Whether the project demonstrates the stated aim of use beyond specialised laboratory settings.

How it's being covered

Coverage analysisShow details
3 source articles · 3 unique outlets
Outlet political mix: Too few rated· 2 Center · 1 unrated
Where the outlets are based: Asia 67% · Unknown 33%
Outlet political mix
Too few rated
Left
Center
Right
0 outlets
2 outlets
0 outlets
The marker shows coverage balance: each unique outlet counts once. 1 unrated outlet is not included.
Geography
Where the outlets covering this story are based.
3 unique outletsDominant coverage: Asia
How we measure coverage

How outlets' accounts compare

2 framing differences · 2 uncorroborated claims · 2 information gaps
The reports repeat the same account with different emphasis; its central claims are not independently confirmed in the reporting Updat3 read.Compared across 2 reports whose article text Updat3 read; 1 other outlet was checked by headline only.
Framing / emphasis differences
Sources emphasise different angles, actors or consequences of the same reporting.
  • The New Indian Express describes the proposed device as potentially reducing the need for invasive procedures and specialised technical expertise; The Hindu’s headline calls the technology rapid and biopsy-free.
  • The Indian Practitioner emphasizes the research team’s grant selection and the goal of supporting screening where conventional laboratory infrastructure is limited; The New Indian Express provides technical details about piRNA biomarkers, nanopore technology and project partners.
Updat3: These are differences of emphasis, not disputes about what is reported. They do not show that the reported claims are true.
One-sided or uncorroborated claims
Claims that come from one party or one source family and are not independently corroborated.
  • Dr Jackson James said the proposed system would analyse a patient’s blood sample automatically after development and validation.
  • The Hindu headline describes the proposed technology as rapid and biopsy-free.
Updat3: Not independently corroborated yet — treat as a claim, not an established fact.
Not established by the reporting
Information the available reporting does not contain or confirm. This is a gap, not a disagreement.
  • The sources do not specify a timetable for development or validation.
  • The coverage does not report clinical performance results for the proposed device.
Updat3: Updat3 cannot conclude anything about this from the current sources.

Timeline

Developments from this story's sources, dated background we compiled and fact-checked, and our earlier coverage. Each row says which.
  1. In 1928, Greek-American physician Georgios Papanicolaou reported that cells collected from the cervix could help identify cancer; the Pap smear later became a widely used screening test.
    Background · from our historical context
  2. Harald zur Hausen and colleagues identified HPV16 in cervical cancer tissue.
    Background · compiled and fact-checked by Updat3
  3. In 2006, the United States approved the first HPV vaccine, adding primary prevention to screening.
    Background · from our historical context
  4. WHO guidelines recommended HPV testing as an alternative to cytology and visual inspection in cervical screening programmes.
    Background · compiled and fact-checked by Updat3
  5. India’s Ministry of Health and Family Welfare issued an operational framework recommending cervical cancer screening for women aged 30–65.
    Background · compiled and fact-checked by Updat3
  6. By 2021, the World Health Organization’s cervical-cancer screening guideline recommended HPV DNA testing as the preferred primary screening method, including options for self-collected samples.
    Background · from our historical context
  7. India launched Cervavac, its first indigenously developed HPV vaccine.
    Background · compiled and fact-checked by Updat3

How we got here

By 2021, the World Health Organization’s cervical-cancer screening guideline recommended HPV DNA testing as the preferred primary screening method, including options for self-collected samples. The recommendation followed WHO’s 2020 global strategy to eliminate cervical cancer, which set targets for vaccination, screening and treatment by 2030.

In 1928, Greek-American physician Georgios Papanicolaou reported that cells collected from the cervix could help identify cancer; the Pap smear later became a widely used screening test. In 2006, the United States approved the first HPV vaccine, adding primary prevention to screening.

Original sources

3 articles from 3 outlets

Every story links to the reporting it was built from. How we choose sources

Spotted a factual error, a broken link or a misleading summary? Tell us.